Skip to main content
A
A

Main navigation additional

  • Home
  • Contact us
  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • Clinical trials
    • MyRealWorld MG
    • Resources
  • Pipeline
    • Our pipeline
    • Partnered programs
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Investors
  • Careers
    • Dare to do more
    • Benefits
    • Employee stories
    • Find your job
  • News
    • The Latest
    • Press releases
    • Media center
  • About
    • One Team
    • Values
    • Management team
    • Board of directors
    • Grants
    • Contact us
Home

Secondary navigation additional

  • Contact

Secondary/mobile navigation

  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • Clinical trials
    • MyRealWorld MG
    • Resources
  • Pipeline
    • Our pipeline
      • Efgartigimod
      • Cusatuzumab
      • ARGX-117
      • ARGX-118
    • Partnered programs
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Investors
  • Careers
    • Dare to do more
    • Benefits
    • Employee stories
    • Find your job
  • News
    • The Latest
    • Press releases
    • Media center
  • About
    • One Team
    • Values
    • Management team
    • Board of directors
    • Grants
    • Contact us

Breadcrumb

  1. Home
  2. News

The Latest

News
February 1, 2021

argenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis

Breda, the Netherlands
argenx today announced its plan to continue enrollment in the ADHERE trial evaluating subcutaneous (SC) efgartigimod (co-formulated with Halozyme's ENHANZE® drug-delivery technology) in chronic inflammatory demyelinating polyneuropathy (CIDP).
Read
argenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis
argenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis

More Press Releases

News
February 25, 2021

argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021

argenx today announced that it will host a conference call and audio webcast on March 4, 2021 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its full year 2020 financial results and provide a fourth quarter business update.
Read
News
February 5, 2021

argenx announces closing of global offering

argenx SE announced today the closing of its previously announced global offering of an aggregate of 3,593,750 ordinary shares (including ordinary shares represented by American Depositary Shares (ADSs)), which includes the full exercise of the underwriters’ option to purchase 468,750 ordinary...
Read
News
February 4, 2021

argenx announces full exercise of underwriters’ option to purchase additional ADSs

argenx SE announced today that the underwriters of its previously announced global offering of ordinary shares (including ordinary shares represented by American Depositary Shares (ADSs)) have exercised their option to purchase 468,750 additional ADSs in full on the same terms and conditions as the...
Read
Show more Press Releases

Media center

  • ARGX-118
  • CIDP
  • Cusatuzumab
  • Efgartigimod
  • Immune Thrombocytopenia
  • Myasthenia Gravis
  • Pemphigus Vulgaris
  • SIMPLE Antibody Platform
April 7, 2020
SIMPLE Antibody platform / Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform
April 7, 2020
SIMPLE Antibody platform / Combining Somatic Mutations Present in Different in Vivo Affinity-Matured Antibodies Isolated From Immunized Lama Glama Yields Ultra-Potent Antibody Therapeutics
April 7, 2020
SIMPLE Antibody platform / Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy
April 7, 2020
Cusatuzumab / CD70: An emerging target in cancer immunotherapy
April 7, 2020
Cusatuzumab / Phase 1 dose-escalation study of the anti-CD70 antibody ARGX-110 in Advanced Malignancies
  • Load more
TwitterFacebookLinkedInWhatsApp
Home
  • Home
  • Contact us

Footer navigation

  • Home
  • Patients
    • Our commitment
    • Disease areas
    • Patient stories
    • Clinical trials
    • MyRealWorld MG
    • Resources
  • Pipeline
    • Our pipeline
      • Efgartigimod
      • Cusatuzumab
      • ARGX-117
      • ARGX-118
    • Partnered programs
  • Innovation
    • Science of collaboration
    • IIP
    • Case studies
    • Academic collaborators
    • Antibody engineering
    • Partnering opportunities
  • Investors
  • Careers
    • Dare to do more
    • Benefits
    • Employee stories
    • Find your job
  • News
    • The Latest
    • Press releases
    • Media center
  • About
    • One Team
    • Values
    • Management team
    • Board of directors
    • Grants
    • Contact us
2021 © Argenx
Disclaimer
Privacy policy
You are now leaving the argenx web site

This link will take you to a site maintained by a third party, which is responsible for its contents.

OK